About the Authors

Almut Grenz, Hartmut Osswald, Hua Zhang
Department of Pharmacology and Toxicology, Tübingen University Hospital, Tübingen, Germany

Almut Grenz, Tobias Eckle, Holger K Eltzschig
Mucosal Inflammation Program, Department of Anesthesiology and Perioperative Medicine, University of Colorado Health Sciences Center, Denver, Colorado, United States of America

Tobias Eckle, Holger K Eltzschig
Department of Anesthesiology and Intensive Care Medicine, Tübingen University Hospital, Tübingen, Germany

Dan Yang, Katya Ravid
Department of Biochemistry and Whitaker Cardiovascular Institute, Boston University School of Medicine, Boston, Massachusetts, United States of America

Zung Vu Tran
Department of Biostatistics, University of Colorado, Denver, Colorado, United States of America

Karin Klingel
Department of Molecular Pathology, Tübingen University Hospital, Tübingen, Germany

Corresponding Author

holger.eltzschig@uchsc.edu

Competing Interests

Bayer HealthCare has patented the use of the A2BAR agonist BAY 60-6583 in the treatment of different medical conditions. The authors are not associated with Bayer HealthCare and are not involved in the patent application. The authors report no competing interests.

Author Contributions

AG, HO, TE, KR, and HKE designed the experiments/the study. AG, TE, DY, HZ, KK, and KR collected data or did experiments for the study. AG, ZVT, KK, KR, and HKE analyzed the data. AG, HO, ZVT, KR, and HKE contributed to writing the paper.